iShares Genomics Immunology and ETF News

An oil collapse sent Wall Street into a tailspin on Mar 9, indicating that the 11-year-long bull market might soon end. These ETFs may, however, survive the crash.

High drug prices will, again, be a key issue in the 2020 Presidential campaign considering that President Trump has made scant progress on the matter despite much rhetoric.White House press secretary

Faced with pushback from multiple fronts over high drug prices, biopharmaceutical firms are experimenting with new ways to get paid for their priciest offerings, mostly biologics, in a report from the

The new budget proposed by California Governor Gavin Newsom includes a plan to allow the state to contract with generic drug makers to provide medicines to all Californians. He believes that the gover

Can biotech ETFs repeat its success story of 2019 in the election year of 2020?

Here is a look at the 25 best and 25 worst ETFs from the past week. Traders can use this list to find prospective candidates that have deviated too far from their longer-term trends, thereby serving a

The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.

Here is a look at the 25 best and 25 worst ETFs from the past trading month. Traders can use this list to find prospective candidates that have deviated too far from their longer-term trends, thereby

Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.

The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.

Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.

Rising investments, surging demand for personalized medicines and shrinking sequencing costs are a slew of factors favouring the genomics space. We look at a few ETFs that can cash in on this trend.